Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2012

Conditions
Glioblastoma MultiformeGliosarcomaAnaplastic AstrocytomaAnaplastic OligodendrogliomaGlioma
Interventions
DRUG

enzyme-inducing anti-epileptic drugs

Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).

DRUG

enzyme-inducing anti-epileptic drugs

Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Annick Desjardins

OTHER